Document is current
Any future updates will be listed below
-
Authors
Smith, Katherine Nabel https://orcid.org/0000-0002-4429-7075
Algarin, Yanci A. https://orcid.org/0000-0002-7987-7635
Archila, Marjorie
Barbieri, John S. https://orcid.org/0000-0002-5467-4102
Goldman, Nathaniel https://orcid.org/0000-0002-6874-0748
Perez-Chada, Lourdes M. https://orcid.org/0000-0001-7724-7309
Noe, Megan H. https://orcid.org/0000-0001-8481-4711
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (T32GM007753)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (1K23AR078930, 5K23AR073932-05)
Dermatology Foundation (Diversity Research Supplement)
- License Information
-
More Information
Article History
Received: 11 August 2023
Revised: 11 August 2023
Accepted: 9 November 2023
First Online: 12 December 2023
Declarations
:
: Megan Noe has received research grants from Boehringer Ingelheim and Bristol Myers Squibb for projects unrelated to this manuscript. John S Barbieri has received consulting fees from Dexcel Pharma for work unrelated to the present study. Lourdes M Perez-Chada has received funding from the National Psoriasis Foundation and the Group for Research and Assessment for Psoriasis and Psoriatic Arthritis. John Barbieri is an Associate Editor for JAMA Dermatology. Megan Noe is senior editor for the Journal of Psoriasis and Psoriatic Arthritis. Katherine Nabel Smith, Marjorie Archila, Lourdes M. Perez-Chada, and Nathaniel Goldman have nothing to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki and was approved by The Mass General Brigham Institutional Review Board.
: Verbal informed consent was obtained from each prior to participation.
